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Introduction 
 
Materials in the nanometre size range may possess beneficial properties which can 
influence the development of remarkable industrial and engineering applications including 
biotechnological systems.  The formation of hybrid systems comprising nanoparticles and 
biomolecules paves the way from cell markers to biosensing1,2, bioimaging3 and targeted drug 
delivery4,5.  Nanoparticles have been found to be useful in the development of systemic, oral, 
pulmonary, transdermal and other administration routes to study drug targeting, the enhancement 
of drug bioavailability and protection of drug bioactivity and stability6-8.  For instance, 
nanoparticles can be used to enhance oral delivery6,9 by improving the bioavailability of poorly 
absorbed drugs.  They are able to penetrate the cells to facilitate cellular internalization and 
connective tissue permeation, thus enabling the drugs to be delivered efficiently to the targeted 
tissue without clogging capillaries10,11.  Consequently, nanotechnology is now used as potential 
route to study the delivery of anti-leukaemic drugs and used to improve drug diffusion through the 
blood/brain barrier.  Nanoparticles can also act as drug carriers during intravenous injection, which 
allows the carriers to penetrate the membranes of the cells and deliver the drugs to cancerous 
tomours.  A recent literature review has indicated that some nanoparticle-bound antitumour agents 
showed prolonged drug retention in tumours, reduction in tumour growth and prolonged survival 
of tumour bearing animals12-15.  Optical16 and electrochemical17 sensing of biomolecules using 
colloidal gold is widely studied by the conjugation of various biomolecules such as protein A, 
avidin, streptavidin, glucose oxidase, horseradish peroxidise and immunoglobins, etc.. 
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6-Mercaptopurine (6-MP) has achieved a special place in biomedicine, owing to its activity in 
cancer chemotherapy21.  It is one of the oldest antineoplastic drug currently in use and as there is a 
good correlation between the drug’s coordination chemistry (it contains sulphur and nitrogen donor 
sites with potential for binding at N-1, N-3, N-7 and N-9) and its chemotherapeutic activity, it has 
attracted much attention22-24.  The activity of 6-MP on tumour cells is believed to be due to its 
ability to convert these into the corresponding ribosides.  In order to suppress the undesirable side 
effects associated with anti-tumour drugs, metal-drug complexes are currently used as slow release 
prodrugs of 6-MP.  The latter employ coordinated components of certain transition metals like 
platinum and palladium25.  A number of detection methods have been suggested for the 
identification of 6-MP, which include potentiometric titration for tablet assay26, amperometric 
detection at a phthalocyanine-modified electrode27 and spectrophotometry28.  Whilst Zima et al.29 
reported the determination of 6-MP using tast polarography and differential pulse polarography at 
the dropping mercury electrode (DME), Basina et al. studied the electrochemical behaviour of 6-
MP using catalytic cathodic stripping voltammetry30 and found that 6-MP-modified mercury 
electrodes act as promoters for the redox exchange of Cytochrome C. 
 
In the present work, gold nanoparticles have been used as probes for the detection of the anticancer 
drug 6-MP and evidence for their complexation has been obtained using UV-Visible spectroscopy, 
cyclic voltammetry, transmission electron microscopy (TEM), and fluorescent spectroscopy.  
Furthermore, the efficacy of the complexes of 6-MP and colloidal gold is examined with biological 
assays in order to evaluate their antibacterial and antifungal activities. 
 
Experimental 
 
Apparatus 
Samples were characterized by ultraviolet (U.V.)-visible spectroscopy (Perkin-Elmer Lambda 25).  
The path length was 1 cm and matched 1 x 1 cm2 cuvettes were used.  Transmission electron 
microscopy (TEM) was undertaken employing a Tec NIE 10 instrument with an accelerating 
voltage of 120 kV; samples was prepared by mixing aqueous solution of MP (5mM) and gold 
solution (1mM).  Fourier transform infrared (FTIR) spectroscopy was performed using a PE IR 
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SPECTRUM ASCII PEDS 1.60 spectrometer and samples were presented as KBr pellets.  Spectra 
were acquired at room temperature at a resolution of 4 cm-1.  Optical emission spectroscopy was 
carried out using Fluoromax-2, Gram 386 spectrometer.  Cyclic voltammetric studies was 
performed using an Autolab PG Stat 12 electrochemical analyzer in a three electrode cell, using 
platinum wire as the counter electrode and a 50 mM KCl calomel reference electrode.  The scans 
were initiated at – 0.4 V and all electrochemical measurements were performed in a static nitrogen 
atmosphere.  The working electrode used in this work was indium-tin-oxide (ITO) coated with 
colloidal gold and this was prepared in the following manner.  The ITO slides were cleaned 
thoroughly by ultrasonication in water, followed by acetone.  The cleaned glass slides were 
immersed in a solution (2% v/v) of 3-aminopropyl trimethoxysilane (APTMS) in methanol for 20 
hours and subsequently immersed in freshly prepared colloidal gold for another 15 hours to create 
a submonolayer of gold nanoparticles.  For electrode modification, freshly prepared gold plates 
were immersed for 12 hours in 6-MP solution (1 mM in 0.01 M HClO4), to avoid sulphide 
contamination.  This process was repeated for all the electrochemical studies (Scheme 1). 
 
Insert Scheme 1 
 
Materials 
HAuCl 4.3H2O (98 %) and trisodium citrate (99 %, AR) were purchased from CDH and Analytical 
Rasayan respectively.  6 -Mercaptopurine (6-MP) was synthesized according to a modified, 
previously reported procedure32,33 and the purity of the sample ascertained by comparing it with the 
commercial sample obtained from Aldrich.  The reaction scheme is given below (Scheme.2) 
 
Insert Scheme 2 
 
Synthesis of 6-chloropurine 
 
To phosphoryl chloride (200 cm3, 2.2 mol.) was added drop wise water (20 cm3) and, after all the 
water had been added, the mixture was boiled for 1.5 hours to dispel the hydrogen chloride.  The 
mixture was subsequently cooled and the top layer was used for the chlorination of hypoxanthine 
to form 6-dichloropurine.  A mixture of hypoxanthine (8 g) and pyrophosphoryl chloride (64 cm3) 
was heated in a sealed glass tube at 165 ºC for 19 hours.  After cooling, the brown solution was 
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decanted from the solid residue in the tube and the volatile material was removed under reduced 
pressure.  The syrupy residue was poured on to crushed ice (200 g), a small amount of tan 
precipitate removed and the filtrate was repeatedly extracted with portions of diethyl ether (6 x 350 
cm3).  The ethereal solution was allowed to stand over anhydrous potassium carbonate for one hour 
and then over calcium sulphate overnight.  On evaporation of diethyl ether, the crude product (4.3 
g., 43 %), m.p. 175-177 ºC, was obtained.  A small portion was recrystallized from boiling water 
(150 cm3) and was allowed to stand at 0 ºC for 1.5 hours and then filtered through a sintered glass 
funnel. 
 
Preparation of 6-mercaptopurine (6-MP) 
 
A suspension of 6-chloropurine (0.98 g, 6.3 mmol.) and an equimolar quantity of thiourea in 
absolute ethanol (14 cm3) was heated to reflux; the solids dissolved and soon a yellow crystalline 
product precipitated.  After refluxing for one hour, the mixture was chilled and crude 6-MP (0.64 
g) was collected, the product was dried over P2O5 in vacuo at 100°C. 
 
Preparation of citrate capped gold nanoparticles 
HAuCl4.6H2O (1 mM, 500 cm3) was heated and to the boiling solution was added trisodium citrate 
(38.8 mM, 50 cm3) as one portion.  After the addition, the previously yellow solution of gold 
chloride turned wine red in colour and gave a characteristic absorbance at 518 nm in the U.V-
Visible spectrum.  From the TEM measurements, the average diameter of the gold nanoparticles 
was found to be in the range 17-18 nm. 
 
Preparation of 6-mercaptopurine (6-MP) coated gold nanoparticles 
Citrate-stabilized gold nanoparticles (1mM, 50 cm3) were mixed with 6-MP (5 mM) in 2-propanol 
(25 cm3) and stirred effectively for 5 hours until the wine red colour became blue.  The 6-MP 
coated gold nanoparticles were obtained after centrifugation. 
 
Details of Microbial Assay 
Antibacterial and antifungal activities were studied using a disk diffusion method, wherein a 
suspension of both gramme positive and gramme negative organisms were added to sterile nutrient 
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agar at 45 ºC and the mixture was solidified on a Petri dish.  Disks made from filter paper dipped 
in 6-MP and 6-MP-gold were placed on agar plates and the plates were left for one hour at 25 ºC to 
allow a period of pre-incubation diffusion in order to minimize the effects of variation in time 
between the applications of different solutions.  The plates were again incubated, this time at 37 ºC 
for 24 hours, and observed for antibacterial activity by determining the diameters of the zones of 
inhibition for each of the samples. 
 
Results and Discussion 
The plasmon band observed for the wine red colloidal gold at 518 nm in the U.V-Visible spectrum 
is characteristic of gold nanoparticles.  Pure drug shows a maxima at 321 nm The addition of 6-MP 
to colloidal gold results in a reduction in the intensity of this absorption band at 518 nm and 321 
nm corresponding to Au(0) and drug moiety and is accompanied by the emergence of an additional 
peak at 670 nm (Figure 1). 
 
Insert Figure 1 
 
The latter can be verified by a colour change from purple to blue with the addition of drug to 
colloidal gold.  The time dependent UV-Visible spectra were obtained after mixing (0.5 mM) 6-
MP with gold nanoparticles at timed interval of 30 minutes (curves a-d); curve (e) was obtained 
after 5 hours.  The appearance of a new peak is due to the aggregation of gold nanoparticles and 
the replacement of citrate by 6-MP leading to the formation of gold-drug complex. 
 
These observations are in agreement with the data obtained using FT-IR spectroscopy.  6-MP 
exists as tautomer form in the solid state as C=S group and the IR spectrum of free (uncomplexed) 
6-MP (Figure 2) displays absorption bands at 1275 cm-1 due the presence of the C=S group. 
 
Insert Figure 2 
 
This peak was absent in the spectrum of the adsorbed form (Figure 3) apparently confirming the 
existence of complex formation of the 6-MP through the sulphur atom. 
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Insert Figure 3 
 
Fluorescence studies were also undertaken to ascertain the binding of the drug moiety with the 
gold nanoparticles.  Thus, free 6-MP has a broad emission centred at ca. 380 nm when excited at a 
wavelength of 320 nm.  The non-fluorescent gold nanoparticles are transformed into a markedly 
fluorescent species when added to 6-MP, the intensity of fluorescence being decreased when 
colloidal gold is added to the drug (Figure 4). 
 
Insert Figure 4 
 
Insert Figure 5 
 
The fluorescence spectrum of 6-MP was studied with different concentrations of gold 
nanoparticles (Figure 6). 
 
Insert Figure 6 
 
With a gradual increase in concentration of Au(0), (Figure 6b-e), the intensity of 6-MP (Figure 6) 
decreases concomitantly.  Throughout this experiment the concentration of 6-MP remained 
constant and displayed peaks at 424 nm and 368 nm in the emission and excitation spectra 
respectively.  Cyclic voltammetry (cv) was employed using gold nanoparticle-modified electrodes, 
to ascertain the nature of the bond formation and the cyclic voltammograms of the gold 
nanoparticle-modified ITO plate immersed in 0.01 M HClO4 solutions are shown (Figure 7).  The 
scans were initiated at –0.4 V and a reduction peak was observed at +0.69 V, which corresponds to 
the formation of gold oxide. 
 
Insert Figure 7 
 
The electrochemical evaluation of 6-MP capped gold nanoparticles is also shown in Figure 7b.  
Peak 1 shows the cv response for the ITO electrode (modified with gold nanoparticles) in 1 mM 
K4Fe(CN)6 at a scan rate of 10 mv/s.  After the exposure of gold electrode in the 6-MP solution, a 
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reduction in the peak current is observed due to the binding of 6-MP with the nanoparticles and 
more pronounced changes in the electrochemical profile of the gold electrode occur as the 6-MP 
concentration increases (Figure 7b).  In fact, the onset of gold oxide formation is heralded by the 
change to a positive potential, indicating that the 6-MP molecule has been spontaneously adsorbed 
on the gold surface.  However at more positive potentials, a large anodic current was obtained, 
which should correspond to the oxidative desorption of the previously adsorbed molecule35, and a 
reduction peak was absent when the gold electrode surface was completely adsorbed by 6-MP.  
The shape of the voltammograms for [Fe(CN)6]3- and [Fe(CN)6]4- at the coated and uncoated 
substrates indicates that the current is primarily controlled by linear diffusion and suggest that the 
monolayer does not completely block electron transfer, as these small molecules provide only a 
partial barrier.  This decrease in both anodic and cothodic current is due to blocking behaviour of 
MP on gold modified electrode (Scheme 3). 
 
Insert Scheme 3 
 
The TEM image (Figure 8) displays clearly aggregates of gold nanoparticles: colloidal gold has an 
average diameter of ca. 18 nm.  On the addition of gold, aggregation of the gold takes place (this 
phenomenon was previously illustrated in Schemes 2 and 3). 
 
Insert Figure 8 
 
Determination of the antibacterial and antifungal activity of the 6-MP-colloidal gold complex 
 
Table 1 details the growth inhibition effected by drug-coated gold nanoparticles against both 
gramme positive and gramme negative organisms viz Micrococcus luteus, Staphylococcus aureus, 
Pseudomonas aeruginosa and E-Coli.  It was observed that the coated colloid was most effective 
for gramme negative organisms and the levels of inhibition can be seen clearly in Figure 9. 
 
Figure 9 Antibacterial activity of 6-MP and 6-MP-covered gold. (a) Micrococcus luteus (b) 
Staphylococcus luteus (c) E-Coli (d) Staphylococcus aureus 
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Table 1 Antibacterial activity of 6-mercaptopurine (6-MP) 
 
6-MP also shows a good antifungal activity against Aspergillus fumigatus and Aspergillus niger 
and these activity levels were found to be enhanced on the addition of colloidal gold (Table 2 and 
Figure 10).  The colloidal gold solution alone does not show any appreciable antifungal and 
antibacterial activities. 
 
Insert Figure 10 
 
Table 2 Antifungal activity of 6-mercaptopurine (6-MP) 
 
Although these preliminary studies demonstrate the effectiveness of the gold-drug complex, the 
precise mechanism by which it operates is not yet known and work continues to investigate this 
further.  Some gold-drugs, namely aurothiomalate and aurothioglucose, have already been 
evaluated for activity against human immunodeficiency virus (HIV) for the treatment of AIDS44,45 
and, in the same way, gold-drugs have been explored for their effectiveness as antifungal, 
antibacterial and anticancer agents.  Gold-drugs are used more as last-line modes of treatment for 
severe cases of rheumatoid arthritis in favour of organic drugs.  It gives more potent and reduced 
toxic side effects.  These properties may be due to geomentry of the complex.  The normal mode of 
 
Levels of Zone of inhibition 
 
Micro organisms 
 
Nature of organisms
Pure 6-MP 6-MP-coated gold 
nanoparticles 
Micrococcus luteus Gramme Positive 41 45 
Staphylococcus aureus Gramme Positive 49 57 
Pseudomonas aeruginosa Gramme Negative 51 63 
E-Coli Gramme Negative 60 72 
 
Levels of Zone of inhibition 
 
Fungal Organisms 
Pure 6-MP 6-MP-coated gold nanoparticles 
Aspergillus fumigatus 45 59 
Aspergillus niger 32 37 
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metabolite pathway and the release mechanism may be altered (favourably in some cases) by the 
presence of metal nanoparticles, to attain a greater efficiency and reduced side effects. 
 
Conclusions 
 
The binding of 6-mercaptopurine (6-MP) to colloidal gold via complexation through the thiol 
group was studied using different analytical techniques (e.g. U.V-Visible spectroscopy, cyclic 
voltammetry, transmission electron microscopy, fluorescence spectroscopy and IR spectroscopy).  
Fluorescence and electrochemical studies have shown the nature of interaction and will be used in 
future studies.  The combination of gold with 6-MP results in a more potent complex compared 
with the individual parts. 
 
Acknowledgement 
The authors thank Dr Brendan J. Howlin (Chemistry Division, University of Surrey) for useful 
discussions in the preparation of this manuscript. 
 
References 
1. Bruchez M Jr, Moronne M, Gin P, Weiss S; Alivistas AP. Science 1998;281:2013-2016 
2. Lahav M, Shipway AN, Willner, I. J Chem Soc Perkin Trans 2 1999;1925-1931 
3. Djalali R, Chen Y, Matsui, H. J Am Chem Soc 2002;124:13660-13661 
4. West JL, Halas NJ. Curr Opin Biotechnol 2000;11:215-217 
5. Hermanson GT, editor. Bioconjugate Techniques. Academic Press: San Diego, 1996 
6. Maincent P, Le Verge R, Sade P, Couvreur P, Devissaguet JP. J Pharm Sci 1986;75:955-958 
7. Zeltner TB, Sweeney TD, Skornik WA, Feldman HA, Brain JD. J Appl Physiol 1991;70:1137-
1145 
8. Cappel MJ, Kreuter J. J Microencapsul 1991;8:369-374 
9. Brannon-Peppas L. Int J Pharm 1995;116:1-9 
10. Couvreur P, Tulkens P, Roland M, Trouet A, Speiser I. FEBS Lett 1997;84(2):323-326 
Page 10 of 28 
11. Astier A, Doat B, Ferrer MJ, Benoit G, Fleury J, Rolland A, Leverge R. Cancer Res 
1998;48:1835-1841 
12. Beck P, Kreuter J, Reszka R, Fichtner I. J Microencapsul 1993;10:101-114 
13. Simeonova M, Ilarionova M, Ivanova T, Konstantinov C, Todorov D. Acta Physiol Pharmacol 
Bulg 1991;17:43-49 
14. Bennis S, Chapey C, Couvreur P, Robert J. Eur J Cancer 1994;30A:89-93 
15. Verdun C, Brasseur F, Vranokx H, Couvreur P, Roland M. Cancer Chemother Pharmacol 
1990;26:13-18 
16. Nath N, Chilkoti A. Anal Chem 2002;74:504-509 
17. Raj CR, Okajima T, Ohsaka TJ. Electroanal Chem 2003;593:127-133 
18. Saxena V, Sadoqi M, Kumar S, Shao J. SPIE’s OeMagazine;September 2004:21-23 
19. Jalil R, Nixon JR. J Microencapsul 1990;7:297-325 
20. Mu L, Feng SS. J Controlled Release 2003;86:33-48 
21. Bostrom B, Evdmann G. Am J Pediatr Hematol Oncol 1993;15:80 
22. Innocenti T. Cancer Chemother Pharmacol 1999;43:133 
23. Drerievr, J.; Clin. Chem. (1998) 44, 2511 
24. Mi, T. J. Controlled Release (1997) 44, 19 
25. Chalmers, A. H.; Burdorf, T.; Murray, A. W. Biochem. Pharmacol. (1972) 21, 2662 
26. Nikolic, K.; Velasavic, K. Mikrochim. Acta (1990) 1, 69 
27. Chalmers, A. H. Biochem. Med. (1975) 12, 234 
28. Harber, M.; Maddocks, J. Chromatogr. (1974) 101, 231 
29. Barek, J.; Berka, A.; Dempiirova, L.; Zima, J. Collect. Czech. Chem. Commun. (1986) 51, 
2466 
Page 11 of 28 
30. Banica, I. A.; Gabriel, F.; Contantin, L. Electroanal. (1997) 9, 945 
31. Hayat, A. (Ed.) Colloidal Gold: Principles, Methods and Applications. Academic Press: San 
Diego (1989) Vols 1-3 
32. Elion, G. B.; Hitching, G. H. J. Am. Chem. Soc. (1956) 78, 3508-3510 
33. A.Bendish,P.J,Russell.,JR; Fox, J. J.; J. Am. Chem. Soc.(1954) 76,6077 
34. Yang, D. F.; Al-Mazna, H.; Morin, M. J. Phys. Chem. (1997) 101,1158 
35. Eddowes, M. J.; Hill, H. A. O. J. Am. Chem. Soc. (1979) 101, 4461 
36. (a) Eddowes, M. J.; Hill, H.A.O.; Uosaki, K. J. Am. Chem. Soc. (1979) 101, 7113; (b) 
Eddowes, M. J.; Hill, H.A.O.; Uosaki, K. Bioelectrochem. Bioenerg. (1980) 7, 527; (c) Albery, 
W. J.; Eddowes, M. J.; Hill, H. A. O.; Hillman, A.R. J. Am. Chem. Soc. (1981) 103, 3904. 
37. Taniguchi, I.; Murakami, T.; Toyosawa, K.; Yamaguchi, H.; Yasukouchi, K. J. Electronal. 
Chem. (1982) 131, 397 
38. (a) Taniguchi, I; Toyosawa, K.; Yamaguchi, H. J. Electroanal. Chem. (1982) 140, 187; (b) 
Taniguchi, I; Toyosawa, K.; Yamaguchi, H. J. Chem. Soc. Chem. Commun. (1982) 1032 
39. Kadish, K. M. (Ed.) Electrochemical and spectrochemical studies of biological redox 
components, Adv. Chem. Ser., Vol. 201, American Chemical Society: Washington, D.C. (1982) 
Chapters. 7-9 and references cited therein 
40. (a) Betso, S.-R.; Klapper, M. H.; Anderson, L. B. J. Am. Chem. Soc. (1972) 94, 8197; (b) 
Tarasevich, M.-R.; Bogdanovskaya, V.-A. Bioelectrochem. Bioenerg. (1976) 3, 589; (c) 
Cotton, T. M.; Schultz, S. G.; van Duyne, R. P. J. Am. Chem. Soc. (1980) 102, 7960; (d) 
Haladjian, J.; Bianco, P.; Serre, P.-A. J. Electroanal. Chem. (1980) 106, 397 
41. Busby, C. C. and Creighton J. A., J. Electroanal. Chem. (1982) 140, 379 
42. Okada, T.; Patterson, B. K.; Ye, S.-Q.; Gurney, M. E. Virology (1993) 192, 631 
Page 12 of 28 
43. Yamaguchi, K.; Ushijima, H.; Hisano, M.; Inoue, Y.; Shimamura, T.; Hirano, T.; Muller, E. G. 
W. Microbiol. Immunol. (2001) 45, 549. 
 
Page 13 of 28 
 
               
Figure 1 The time dependent UV-Visible obtained after mixing (0.5 mM) 6-mercaptopurine with 
gold nanoparticles at time intervals of 30 minutes 
a-e 
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Figure 2 FTIR transmission spectrum of pure 6-mercaptopurine (6-MP) 
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Figure 3 FTIR transmission spectrum of 6-MP with gold nanoparticles (MP-AU) 
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Figure 4 Emission spectra of (a) free 6-MP (5 mM) and (b) the adsorbed species on gold (1 mM, 
0.5 cm3) nanoparticles taken in aqueous medium at intervals of 30 min. 
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Figure 5 Excitation spectra taken in aqueous medium for (a) free 6-MP (5 mM) and (b) the 
adsorbed species on gold nanoparticles (1 mM) 
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Figure 6. Emission spectra taken in aqueous medium for (a) free 6-MP (5 mM) and (b-e) for the 
adsorbed species on gold nanoparticles.  The concentration of gold solution is varied (0.5cm3 – 2 
cm3 of 1mM gold solution), but the analysis time is kept constant (2 minutes) 
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(a) 
(b)  
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(c)  
 
Figure 7:  Cyclic voltammograms of a gold nanoparticle-modified electrode (a) in the 
absence of 6-MP in 0.01 M HClO4. M, (b) in the presence of different concentrations of 
6-MP in 0.01 M HClO4. (a) 50 (b) 100 and (c) 150 μM.  The scan rate is maintained at 
0.02 V s-1. and (c) in 1mM K4Fe(CN)6 at a scan rate of 10 mV s-1. 
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                                         (a)                                                                     (b)                     
(c) 
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Figure 8 Transmission electron micrographs of 6-MP-covered gold nanoparticles of average 
diameter 20 nm.  The samples were prepared from an aqueous solution: (a) gold nano particle; (b) 
6-MP-covered gold nanoparticles; (c) expanded portion of 6-MP covered gold nanoparticles 
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Figure 9 Antibacterial activity of 6-MP and 6-MP-covered gold. (a) Micrococcus luteus (b) 
Staphylococcus luteus (c) E-Coli (d) Staphylococcus aureus 
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Figure 10. Antifungal activities of 6-MP and 6-MP-covered gold (a) Aspergillus fumigatus (b) 
Aspergillus niger 
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          Scheme1. Aggregation of 6-MP on Gold nanoparticles 
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Table 1 Antibacterial activity of 6-mercaptopurine (6-MP) 
 
Table 2 Antifungal activity of 6-mercaptopurine (6-MP) 
 
  
 
 
Levels of Zone of inhibition 
 
Micro organisms 
 
Nature of organisms
Pure 6-MP 6-MP-coated gold 
nanoparticles 
Micrococcus luteus Gramme Positive 41 45 
Staphylococcus aureus Gramme Positive 49 57 
Pseudomonas aeruginosa Gramme Negative 51 63 
E-Coli Gramme Negative 60 72 
 
Levels of Zone of inhibition 
 
Fungal Organisms 
Pure 6-MP 6-MP-coated gold nanoparticles 
Aspergillus fumigatus 45 59 
Aspergillus niger 32 37 
